

Supplemental Figure Legends

Supplemental Figure S1. Serum cytokine levels after acute/subacute exposure to immune stimulation in adult mice. Serum IL-6 levels obtained from trunk blood were quantified by ELISA in adult female mice exposed to either normal saline (n=8; black column) or poly(I:C) (n=8; gray column) daily for 3 days. Bar graph indicates group mean and error bar indicates standard deviation. Asterisk indicates $p < 0.05$.

Supplementary Figure S1




Table S1. Demographic, postmortem, and clinical characteristics of human subjects used in this study.

Healthy Comparison Subjects									Subjects with Schizophrenia													
Pair	Case	Sex/ Race	Age	PMI ^a	Storage Time ^b	RIN	pH	Cause of Death	Case	DSM IV diagnosis	Sex/ Race	Age	PMI ^a	Storage Time ^b	RIN	pH	Cause of Death	NSAID ATOD	Tobacco ATOD	Anti- psychotic ATOD	Anti- depressant ATOD	Benzodiazepine/ Anticonvulsant ATOD
1	592	M/B	41	22.1	212	9.0	6.7	ASCVD	533	Chronic undifferentiated schizophrenia	M/W	40	29.1	222	8.4	6.8	Accidental Asphyxiation	No	Unknown	Yes	No	No
2	567	F/W	46	15.0	214	8.9	6.7	Mitral valve prolapse	537	Schizoaffective disorder	F/W	37	14.5	219	8.6	6.7	Suicide by hanging	No	Unknown	No	No	No
3	516	M/B	20	14.0	222	8.4	6.9	Homicide by gun shot	547	Schizoaffective disorder	M/B	27	16.5	218	7.4	7.0	Heat Stroke	No	Unknown	Yes	Yes	Yes
4	630	M/W	65	21.2	205	9.0	7.0	ASCVD	566	Chronic undifferentiated schizophrenia; AAR	M/W	63	18.3	215	8.0	6.8	ASCVD	No	Yes	Yes	Yes	Yes
5	604	M/W	39	19.3	208	8.6	7.1	Hypoplastic coronary artery	581	Chronic paranoid schizophrenia; ADC; OAC	M/W	46	28.1	213	7.9	7.2	Accidental combined drug overdose	No	Unknown	Yes	No	Yes
6	546	F/W	37	23.5	220	8.6	6.7	ASCVD	587	Chronic undifferentiated schizophrenia; AAR	F/B	38	17.8	213	9.0	7.0	Myocardial hypertrophy	No	Yes	Yes	No	Yes
7	551	M/W	61	16.4	219	8.3	6.6	Cardiac tamponade	625	Chronic disorganized schizophrenia; AAC	M/B	49	23.5	207	7.6	7.3	ASCVD	No	Yes	Yes	Yes	No
8	685	M/W	56	14.5	198	8.1	6.6	Hypoplastic coronary artery	622	Chronic undifferentiated schizophrenia	M/W	58	18.9	205	7.4	6.8	Right MCA infarction	No	Unknown	No	No	No
9	681	M/W	51	11.6	200	8.9	7.2	Hypertrophic cardiomyopathy	640	Chronic paranoid schizophrenia	M/W	49	5.2	205	8.4	6.9	Pulmonary embolism	No	Unknown	Yes	Yes	No
10	806	M/W	57	24.0	177	7.8	6.9	Pulmonary embolism	665	Chronic paranoid schizophrenia; ADC	M/B	59	28.1	201	9.2	6.9	Intestinal hemorrhage	No	Yes	Yes	Yes	No
11	822	M/B	28	25.3	174	8.5	7.0	ASCVD	787	Schizoaffective disorder; ODC	M/B	27	19.2	181	8.4	6.7	Suicide by gun shot	No	No	Yes	No	No
12	727	M/B	19	7.0	192	9.2	7.2	Trauma	829	Schizoaffective disorder; ADC; OAR	M/W	25	5.0	172	9.3	6.8	Suicide by salicylate overdose	Yes	Yes	No	No	Yes
13	871	M/W	28	16.5	165	8.5	7.1	Trauma	878	Disorganized schizophrenia; ADC	M/W	33	10.8	165	8.9	6.7	Myocardial fibrosis	No	Yes	Yes	Yes	Yes
14	575	F/B	55	11.3	215	9.6	6.8	ASCVD	517	Disorganized schizophrenia; ADC	F/W	48	3.7	224	9.3	6.7	Intracerebral hemorrhage	No	Yes	Yes	No	No
15	700	M/W	42	26.1	196	8.7	7.0	ASCVD	539	Schizoaffective disorder; ADR	M/W	50	40.5	220	8.1	7.1	Suicide by combined drug overdose	Yes	Unknown	Yes	Yes	Yes
16	988	M/W	82	22.5	144	8.4	6.2	Trauma	621	Chronic undifferentiated schizophrenia	M/W	83	16.0	208	8.7	7.3	Accidental asphyxiation	No	Unknown	No	No	No
17	686	F/W	52	22.6	199	8.5	7.0	ASCVD	656	Schizoaffective disorder; ADC	F/B	47	20.1	204	9.2	7.3	Suicide by gun shot	Yes	Yes	Yes	No	No
18	634	M/W	52	16.2	206	8.5	7.0	ASCVD	722	Chronic undifferentiated schizophrenia; ODR; OAR	M/B	45	9.1	194	9.2	6.7	Upper GI bleeding	No	Yes	Yes	No	No
19	852	M/W	54	8.0	167	9.1	6.8	Cardiac tamponade	781	Schizoaffective disorder; ADR	M/B	52	8.0	182	7.7	6.7	Peritonitis	No	Yes	Yes	Yes	No
20	987	F/W	65	21.5	144	9.1	6.8	ASCVD	802	Schizoaffective disorder; ADC; ODR	F/W	63	29.0	179	9.2	6.4	Right ventricular dysplasia	No	Yes	Yes	No	Yes
21	818	F/W	67	24.0	176	8.4	7.1	Anaphylactic reaction	917	Chronic undifferentiated schizophrenia	F/W	71	23.8	156	7.0	6.8	ASCVD	No	Yes	Yes	No	No
22	857	M/W	48	16.6	166	8.9	6.7	ASCVD	930	Disorganized schizophrenia; ADR; OAR	M/W	47	15.3	152	8.2	6.2	ASCVD	No	Yes	Yes	No	Yes
23	739	M/W	40	15.8	191	8.4	6.9	ASCVD	933	Disorganized schizophrenia	M/W	44	8.3	152	8.1	5.9	Myocarditis	No	No	Yes	Yes	Yes
24	1047	M/W	43	13.8	133	9.0	6.6	ASCVD	1209	Schizoaffective disorder	M/W	35	9.1	114	8.7	6.5	Suicide by diphenhydramine overdose	Yes	No	Yes	No	No
25	1086	M/W	51	24.2	129	8.1	6.8	ASCVD	10025	Disorganized schizophrenia; OAR	M/B	52	27.1	108	7.8	6.7	ASCVD	No	Yes	No	No	No
26	1092	F/B	40	16.6	127	8.0	6.8	Mitral valve prolapse	1178	Schizoaffective disorder	F/B	37	18.9	118	8.4	6.1	Pulmonary embolism	No	Yes	Yes	No	Yes
27	10005	M/W	42	23.5	116	7.4	6.7	Trauma	1256	Undifferentiated schizophrenia	M/W	34	27.4	108	7.9	6.4	Suicide by hanging	No	No	Yes	No	No
28	1336	M/W	65	18.4	92	8.0	6.8	Cardiac tamponade	1173	Disorganized schizophrenia; ADR	M/W	62	22.9	118	7.7	6.4	ASCVD	No	Yes	Yes	No	No
29	1122	M/W	55	15.4	123	7.9	6.7	Cardiac tamponade	1105	Schizoaffective disorder	M/W	53	7.9	125	8.9	6.2	ASCVD	No	Yes	Yes	No	No

Healthy Comparison Subjects									Subjects with Schizophrenia													
Pair	Case	Sex/ Race	Age	PMI ^a	Storage Time ^b	RIN	pH	Cause of Death	Case	DSM IV diagnosis	Sex/ Race	Age	PMI ^a	Storage Time ^b	RIN	pH	Cause of Death	NSAID ATOD	Tobacco ATOD	Anti- psychotic ATOD	Anti- depressant ATOD	Benzodiazepine/ Anticonvulsant ATOD
30	1284	M/W	55	6.4	102	8.7	6.8	ASCVD	1188	Undifferentiated schizophrenia; AAR; OAR	M/W	58	7.7	117	8.4	6.2	ASCVD	No	Yes	Yes	No	No
31	1191	M/B	59	19.4	118	8.4	6.2	ASCVD	1263	Undifferentiated schizophrenia; ADR	M/W	62	22.7	108	8.5	7.1	Accidental asphyxiation	Yes	Yes	Yes	Yes	No
32	970	M/W	42	25.9	145	7.2	6.4	ASCVD	1222	Undifferentiated schizophrenia; AAC	M/W	32	30.8	112	7.5	6.4	Suicide by combined drug overdose	No	No	Yes	Yes	No
33	10003	M/W	49	21.2	116	8.4	6.5	Trauma	1088	Undifferentiated schizophrenia; ADC; OAC	M/W	49	21.5	127	8.1	6.5	Accidental combined drug overdose	No	Yes	Yes	Yes	No
34	1247	F/W	58	22.7	108	8.4	6.4	ASCVD	1240	Undifferentiated schizophrenia; ADR	F/B	50	22.9	109	7.7	6.3	ASCVD	Yes	Yes	Yes	No	No
35	1324	M/W	43	22.3	94	7.3	7	Aortic dissection	10020	Schizophrenia, paranoid type; AAC; OAC	M/W	38	28.8	108	7.4	6.6	Suicide by salicylate overdose	Yes	Yes	Yes	Yes	Yes
36	1099	F/W	24	9.1	126	8.6	6.5	Cardiomyopathy	10023	Disorganized schizophrenia	F/B	25	20.1	107	7.4	6.7	Suicide by drowning	No	No	Yes	No	Yes
37	1307	M/B	32	4.8	97	7.6	6.7	ASCVD	10024	Paranoid schizophrenia	M/B	37	6.0	107	7.5	6.1	ASCVD	Yes	No	No	No	No
38	1391	F/W	51	7.8	85	7.1	6.6	ASCVD	1189	Schizoaffective disorder; AAR	F/W	47	14.4	119	8.3	6.4	Suicide by combined drug overdose	Yes	Yes	Yes	Yes	Yes
39	1282	F/W	39	24.5	105	7.5	6.8	ASCVD	1211	Schizoaffective disorder	F/W	41	20.1	116	7.8	6.3	Sudden unexplained death	Yes	Yes	Yes	Yes	No
40	1159	M/W	51	16.7	122	7.6	6.5	ASCVD	1296	Undifferentiated schizophrenia	M/W	48	7.8	102	7.3	6.5	Pneumonia	No	Yes	Yes	Yes	No
41	1326	M/W	58	16.4	96	8.0	6.7	ASCVD	1314	Undifferentiated schizophrenia	M/W	50	11.0	99	7.2	6.2	ASCVD	Yes	No	Yes	Yes	No
42	902	M/W	60	23.6	161	7.7	6.7	ASCVD	1361	Schizoaffective disorder; ODC	M/W	63	23.2	91	7.7	6.4	Cardiomyopathy	No	Yes	Yes	No	Yes
43	1374	M/W	43	21.7	88	7.2	6.6	ASCVD	904	Schizoaffective disorder	M/W	33	28.0	160	7.1	6.2	Pneumonia	No	Yes	Yes	No	Yes
44	1555	M/W	17	15.1	53	7.9	6.9	Trauma	1649	Undifferentiated schizophrenia	M/B	17	21.4	39	8.1	6.9	Suicide by hanging	No	No	Yes	Yes	No
45	1268	M/B	49	19.9	106	7.9	7.1	ASCVD	1230	Undifferentiated schizophrenia	M/W	50	16.9	111	8.2	6.6	Suicide by doxepin overdose	No	Yes	Yes	Yes	No
46	1466	F/B	64	20.0	72	8.8	6.7	Trauma	1341	Schizoaffective disorder; ODC	F/W	44	24.5	93	8.8	6.6	Trauma	No	No	Yes	No	Yes
47	1518	M/W	50	20.7	61	7.7	6.4	ASCVD	1367	Schizoaffective disorder; ADC; ODR	M/W	47	28.9	91	7.2	6.6	Combined drug overdose	No	No	No	No	No
48	1386	M/W	46	21.2	86	8.3	6.7	ASCVD	1420	Schizoaffective disorder; AAR; ODC; OAR	M/W	47	23.4	80	8.2	6.8	Suicide by jump	No	Yes	Yes	Yes	No
49	1472	M/W	61	23.8	70	8.0	6.5	Pulmonary embolism	1453	Paranoid schizophrenia; ADR	M/W	62	11.1	73	8.2	6.4	Trauma	No	Yes	Yes	No	Yes
50	1026	M/W	59	19.8	137	7.4	6.3	ASCVD	1454	Paranoid schizophrenia; AAR; ODC	M/W	59	24.1	72	7.6	6.1	Trauma	Yes	Yes	Yes	Yes	No
51	694	M/W	38	20.7	198	7.7	7.0	Subarachnoid hemorrhage	1455	Paranoid schizophrenia; AAR; OAC	M/W	42	8.2	72	7.7	6.4	Peritonitis	Yes	Yes	Yes	No	Yes
52	1350	M/W	21	24.2	92	7.3	6.4	Trauma	1474	Schizoaffective disorder; ADR	M/W	37	39.9	70	7.0	6.7	Suicide by hanging	No	No	No	No	No
53	1792	F/W	36	28.1	14	7.5	6.5	Pulmonary embolism	1506	Schizoaffective disorder; ADC	F/W	47	14.1	65	7.5	6.6	Combined drug overdose	No	Yes	Yes	Yes	No
54	1524	M/W	66	9.4	58	8.1	6.4	Intestinal infarction	1542	Paranoid schizophrenia	M/W	65	17.4	55	7.8	6.7	Combined drug overdose	No	Yes	Yes	Yes	Yes
55	1270	F/W	73	19.7	106	7.7	6.7	Trauma	1579	Schizoaffective disorder; ADR; ODC	F/W	69	16.1	49	7.7	6.7	ASCVD	No	Yes	Yes	No	Yes
56	1372	M/W	37	20.5	89	9.0	6.6	Asphyxiation	1581	Paranoid schizophrenia; ODC; OAC	M/W	32	18.4	49	9.0	6.8	ASCVD	No	Yes	Yes	Yes	No
57	1543	F/W	45	17.9	55	7.4	6.8	Subarachnoid hemorrhage	10026	Undifferentiated schizophrenia	F/W	46	23.8	108	7.6	6.6	Suicide by thermal injuries	No	Yes	Yes	Yes	No
58	1583	M/W	58	19.1	49	8.2	6.8	Trauma	1686	Schizophrenia, paranoid type; AAR	M/B	56	14.1	32	8.3	6.2	ASCVD	No	Yes	Yes	Yes	Yes
59	1554	M/W	50	23.2	55	7.6	6.5	ASCVD	1691	Schizophrenia, paranoid type; ADR; ODC	M/W	51	31.9	31	7.7	6.6	Combined drug overdose	Yes	Yes	Yes	No	Yes

Healthy Comparison Subjects									Subjects with Schizophrenia													
Pair	Case	Sex/ Race	Age	PMI ^a	Storage Time ^b	RIN	pH	Cause of Death	Case	DSM IV diagnosis	Sex/ Race	Age	PMI ^a	Storage Time ^b	RIN	pH	Cause of Death	NSAID ATOD	Tobacco ATOD	Anti- psychotic ATOD	Anti- depressant ATOD	Benzodiazepine/ Anticonvulsant ATOD
60	1635	M/W	66	25.3	42	8.2	6.8	Cardiac tamponade	1706	Schizoaffective disorder; AAR; ODC; OAR	M/B	60	28.1	28	8.4	6.8	Sepsis	No	Yes	Yes	No	No
61	1384	M/W	67	21.9	87	7.0	6.6	ASCVD	1712	Schizoaffective disorder; ADR; ODC	M/W	63	15.1	26	7.1	6.2	ASCVD	Yes	No	Yes	Yes	Yes
62	1558	M/W	54	24.4	54	7.7	6.9	ASCVD	1734	Schizophrenia, undifferentiated type; AAR; ODC; OAR	M/W	54	28.6	23	7.7	6.1	Pneumonia	Yes	Yes	Yes	No	No
	Mean	48.7	18.8	131.8	8.2	6.7						47.7	19.2	128.1	8.1	6.6		16Y/46N	41Y/13N/ 8Unk	54Y/8N	27Y/35N	24Y/38N
	SD	13.8	5.5	56.2	0.6	0.2						12.7	8.5	60.7	0.6	0.3						

^aPMI, postmortem interval (hours); ^b Storage time (months) at -80C; Other abbreviations: ASCVD, arteriosclerotic cardiovascular disease; MCA, middle cerebral artery; ATOD, at time of death; ADC, alcohol dependence, current at time of death; ADR, alcohol dependence, in remission at time of death; AAC, alcohol abuse, current at time of death; AAR, alcohol abuse, in remission at time of death; ODC, other substance dependence, current at time of death; ODR, other substance dependence, in remission at time of death; OAC, other substance abuse, current at time of death; OAR, other substance abuse, in remission at time of death; U, unknown; M, male; F, female; W, white; B, black.

Supplemental Table S2: qPCR primer design

Gene	Species	Accession #	Amplicon Size (bp)	Position	Forward Primer (F) Reverse Primer (R)
Interleukin-1 β (IL-1B)	Human	NM_000576	115	304-418	(F) AAGCTGAGGAAGATGCTGGT (R) CGTTATCCCATGTGTGCGAAG
Interleukin-6 (IL-6)	Human	NM_000600	50	535-584	(F) CCAGAGCTGTGCAGATGAGT (R) TTTCTGCAGGAACTGGATCA
Interleukin-8 (IL-8)	Human	NM_000584	86	205-290	(F) GCTCTGTGTGAAGGTGCAGT (R) GGTGGAAAGTTTGGAGTA
Interferon- β	Human	NM_002176	130	362-491	(F) CTAGCACTGGCTGGAATGAG (R) CTCATGAGTTTCCCTGGT
Nuclear factor- κ B isoform 1 (NF- κ B1)	Human	NM_003998	143	819-961	(F) CACTGTGAGGATGGGATCTG (R) CCCCTTATACACGCCTCTGT
Nuclear factor- κ B isoform 2 (NF- κ B2)	Human	NM_001077494	122	960-1081	(F) TCTCGAATGGACAAGACAGC (R) TGCCATCCATTCTCATCATC
Schnurri-2	Human	NM_006734	148	1610-1757	(F) CGAGGCTTCTGACAAAATGA (R) AGGGAGAGGAATCCCCTTT
Beta actin	Human	NM_001101	101	1146-1246	(F) GATGTGGATCAGCAAGCA (R) AGAAAGGGGTGTAACGCAACTA
Cyclophilin	Human	NM_021130	126	159-284	(F) GCAGACAAGGTCCCAAAG (R) GAAGTCACCACCCTGACAAC
Glyceraldehyde-3- phosphate dehydrogenase (GAPDH)	Human	NM_002046	87	556-642	(F) TGCACCACCAACTGCTTAGC (R) GGCATGGACTGTGGTCATGAG
Interferon-induced transmembrane protein 1 (IFITM1)	Mus musculus	NM_026820	50	143-192	(F) AAAAGCCGAGAGATGCCTAA (R) GACCCAGTACAACCACCTC
Interferon-induced transmembrane protein 2 (IFITM2)	Mus musculus	NM_030694	62	558-619	(F) CGCGTATGCAAATGTTACCT (R) ACCCCGTGCACTTTATTGA
Interferon-induced transmembrane protein 3 (IFITM3)	Mus musculus	NM_025378	57	476-532	(F) TCATCATTGTTCTTAACGCTCA (R) CGGAAGTCGGAATCCTCTAT
IL-1B	Mus musculus	NM_008361	98	360-457	(F) GAAGAAGAGCCCATCCTCTG (R) TCATCTCGGAGCCTGTAGTG
IL-6	Mus musculus	NM_031168	108	118-225	(F) AGTCCGGAGAGGAGACTTCA (R) ATTTCCACGATTTCCAGAG
NF- κ B1	Mus musculus	NM_008689	114	1941-2054	(F) CATCCACCATGGAAGACAAG (R) TCACTGCGTAGTCGAAAAGG
NF- κ B2	Mus musculus	NM_019408	126	997-1122	(F) ATCTCCCGAATGGACAAGAC (R) TTGCCATCCATTCTCATCAT
Schnurri-2	Mus musculus	NM_010437	82	5774-5855	(F) CACCTTCAAATCCTCCGTTT (R) CGTGGTCTTGGTGTTCATC
Beta actin	Mus musculus	NM_007393	95	955-1049	(F) CCTCTATGCCAACACAGTGC (R) TGCTAGGAGCCAGAGCAGTA
Cyclophilin	Mus musculus	NM_008907	63	383-445	(F) CTGCACTGCCAAGACTGAAT (R) CCTTCTTTCACCTTCCCAA

GAPDH	Mus musculus	NM_008084	64	431-494	(F) CATGTTTGTGATGGGTGTGA (R) TGCATTGCTGACAATCTTGA
IL-1B	Macaca mulatta	NM_001042756	115	217-331	(F) AAGCTAAGGAAGATGCTGGT (R) CGTTATTGCGTGTGTGCGAGG
IL-6	Macaca mulatta	NM_001042733	50	419-468	(F) CCAGAGCTGTGCAAATGAGT (R) TTTCTGCAGGAACTGGATCA
NF-κB1	Macaca mulatta	NM_001266053	143	481-623	(F) CACTGTGAGGATGGGATCTG (R) CCCCTTATACACGCCTCTGT
NF-κB2	Macaca mulatta	XM_001104566	122	890-1011	(F) TCTCGAATGGACAAGACAGC (R) TGCCATCCATTCTCATCATC
Schnurri-2	Macaca mulatta	XM_001092694	54	6509-6562	(F) CGGAGGGTCCTGATGACTAT (R) GTTGCTGAGAGTGGAGTGGA
Beta actin	Macaca mulatta	NM_001033084	101	1087-1187	(F) GATGTGGATCAGCAAGCA (R) AGAAAGGGTGTAACGCAACTA
Cyclophilin	Macaca mulatta	NM_001032809	126	76-201	(F) GCAGACAAGGTTCCAAAG (R) GAAGTCACCACCCTGACAC
GAPDH	Macaca mulatta	XM_001105471	93	527-619	(F) TGCACCACCAACTGCTTAGC (R) AGTGATGGCGTGGACTGTG

Table S3. Table of poly(I:C)-exposed pregnant mice and outcomes.

Gestational Exposure Time Frame	Injection	Injected Pregnant Mice (n)	Not pregnant or no pups (n)	Mothers that cannabilized pups (n)	Mothers with failure to thrive pups (n)	Mothers with healthy pups (n)	Mean offspring per mother (SD)^a	Total male offspring studied (n)^b	Total female offspring studied (n)^b
E11-13	Poly(I:C)	12	2	1	2	7	6.9 (2.0)	7	7
E11-13	Normal Saline	12	3	0	1	8	6.5 (1.1)	7	7
E15-17	Poly(I:C)	12	2	0	0	10	5.3 (1.8)	8	8
E15-17	Normal Saline	12	3	1	0	8	5.4 (1.7)	8	8

^aThe mean number of offspring per mother with healthy pups did not differ between poly(I:C)-injected mothers and normal saline-injected mothers at E11-13 ($t_{13}=0.43$, $p=.67$) or E15-17 ($t_{14}=0.15$, $p=.89$). ^bOnly one male and/or female offspring per injected mother was included in the study.

Supplemental Table S4. Effects of maternal immune activation on immune system-related mRNA levels in the frontal cortex of adult offspring

Immune Marker	<i>E11-13 Maternal Injections</i>			<i>E15-17 Maternal Injections</i>		
	Normal Saline	Poly(I:C)	T test	Normal Saline	Poly(I:C)	T test
IFITM1						
<i>Male</i>	0.00101 ± 0.00027	0.00094 ± 0.00021	p=.64	0.00108 ± 0.00012	0.00106 ± 0.00021	p=.77
<i>Female</i>	0.00092 ± 0.00019	0.00091 ± 0.00014	p=.89	0.00094 ± 0.00029	0.00087 ± 0.00015	p=.55
<i>All</i>	0.00096 ± 0.00023	0.00093 ± 0.00017	p=.63	0.00101 ± 0.00023	0.00096 ± 0.00020	p=.53
IFITM2						
<i>Male</i>	0.00065 ± 0.00017	0.00060 ± 0.00014	p=.53	0.00065 ± 0.00009	0.00066 ± 0.00015	p=.89
<i>Female</i>	0.00063 ± 0.00008	0.00066 ± 0.00012	p=.52	0.00067 ± 0.00012	0.00067 ± 0.00008	p=.95
<i>All</i>	0.00064 ± 0.00013	0.00063 ± 0.00013	p=.85	0.00066 ± 0.00010	0.00067 ± 0.00012	p=.88
IFITM3						
<i>Male</i>	0.0134 ± 0.0015	0.0125 ± 0.0022	p=.37	0.0141 ± 0.0018	0.0139 ± 0.0019	p=.86
<i>Female</i>	0.0148 ± 0.0040	0.0138 ± 0.0015	p=.57	0.0143 ± 0.0020	0.0141 ± 0.0018	p=.87
<i>All</i>	0.0141 ± 0.0015	0.0131 ± 0.0019	p=.33	0.0142 ± 0.0018	0.0140 ± 0.0018	p=.80
IL-1B						
<i>Male</i>	0.000069±0.000021	0.000069 ± 0.000017	p=.99	0.000068±0.000028	0.000080±0.000029	p=.42
<i>Female</i>	0.000091±0.000077	0.000065 ± 0.000016	p=.39	0.000063±0.000011	0.000053±0.000012	p=.09
<i>All</i>	0.000080±0.000055	0.000067 ± 0.000016	p=.40	0.000066±0.000020	0.000066±0.000026	p=.94
IL-6						
<i>Male</i>	0.000017±0.000005	0.000015±0.000005	p=.57	0.000016±0.000004	0.000016±0.000007	p=.99
<i>Female</i>	0.000017±0.000007	0.000014±0.000006	p=.49	0.000015±0.000003	0.000016±0.000005	p=.99
<i>All</i>	0.000017±0.000006	0.000015±0.000005	p=.35	0.000016±0.000004	0.000016±0.000006	p=.99
NK-κB1						
<i>Male</i>	0.0046 ± 0.0005	0.0045 ± 0.0003	p=.65	0.0046 ± 0.0003	0.0045 ± 0.0005	p=.63
<i>Female</i>	0.0047 ± 0.0002	0.0045 ± 0.0003	p=.26	0.0044 ± 0.0006	0.0044 ± 0.0002	p=.73
<i>All</i>	0.0047 ± 0.0004	0.0045 ± 0.0003	p=.30	0.0045 ± 0.0005	0.0044 ± 0.0003	p=.56
NK-κB2						
<i>Male</i>	0.00098 ± 0.00014	0.00099 ± 0.00009	p=.94	0.00093 ± 0.00011	0.00093 ± 0.00016	p=.94
<i>Female</i>	0.00097 ± 0.00012	0.00095 ± 0.00014	p=.71	0.00090 ± 0.00019	0.00089 ± 0.00011	p=.93
<i>All</i>	0.00098 ± 0.00013	0.00097 ± 0.00011	p=.82	0.00092 ± 0.00015	0.00091 ± 0.00014	p=.90
Schnuri2						
<i>Male</i>	0.0795 ± 0.0157	0.0779 ± 0.0112	p=.84	0.0811 ± 0.0065	0.0833 ± 0.0083	p=.57
<i>Female</i>	0.0794 ± 0.0052	0.0778 ± 0.0069	p=.63	0.0794 ± 0.0121	0.0778 ± 0.0044	p=.73
<i>All</i>	0.0794 ± 0.0112	0.0779 ± 0.0089	p=.69	0.0802 ± 0.0095	0.0805 ± 0.0070	p=.92

Values are mean ± standard deviation. Seven male and seven female offspring from the E11-13 maternal injections and eight male and eight female offspring from the E15-17 maternal injections were included in the study. IL-8 and interferon-β were not expressed at detectable levels in frontal cortex and were not quantified.